Baird Medical Concludes Successful Participation at ACS Clinical Congress 2025 with Strong Interest in MWA Technology
Baird Medical (NASDAQ: BDMD) concluded participation at the ACS Clinical Congress 2025 (October 5–7), showcasing its minimally invasive microwave ablation (MWA) systems to a global surgical audience.
At the exhibit, the company's advanced MWA technology drew significant surgeon interest across specialties, with live demonstrations focused on applications for thyroid nodules, breast disease, and other conditions. The company reported high engagement and renewed discussions with surgical and interventional leaders from leading institutions, and said it will pursue expanded U.S. and international partnerships building on congress momentum.
Baird Medical (NASDAQ: BDMD) ha concluso la partecipazione al ACS Clinical Congress 2025 (5–7 ottobre), presentando i suoi sistemi minimamente invasivi di ablazione a microonde (MWA) a un pubblico chirurgico globale.
Alla fiera, la tecnologia avanzata di MWA dell'azienda ha suscitato notevole interesse tra i chirurghi di diverse specialità, con dimostrazioni dal vivo focalizzate su applicazioni per noduli tiroidei, patologie della mammella e altre condizioni. L'azienda ha registrato alto coinvolgimento e rinnovate discussioni con leader chirurgici e interventistici di istituzioni di primo piano, e ha dichiarato che mirerà a nuove partnership negli Stati Uniti e a livello internazionale, sfruttando lo slancio del congress.
Baird Medical (NASDAQ: BDMD) concluyó su participación en el ACS Clinical Congress 2025 (5-7 de octubre), mostrando sus sistemas de ablación por microondas (MWA) mínimamente invasivos a una audiencia quirúrgica global.
En el estand, la tecnología avanzada de MWA de la empresa atrajo un notable interés de cirujanos de diversas especialidades, con demostraciones en vivo centradas en aplicaciones para nódulos tiroideos, enfermedades de la mama y otras condiciones. La empresa reportó alta participación y renovadas conversaciones con líderes quirúrgicos e intervencionistas de instituciones destacadas, y dijo que buscará ampliar asociaciones en EE. UU. e a nivel internacional, aprovechando el impulso del congreso.
베어드 메디컬(Baird Medical, NASDAQ: BDMD)은 ACS Clinical Congress 2025에 참여를 마치고 5일–7일에 걸쳐 전 세계 수술 커뮤니티에 미적용의 마이크로파 절제술(MWA) 시스템을 선보였습니다.
전시장에서 회사의 첨단 MWA 기술은 다양한 전문 분야의 수술 의사들 사이에서 큰 관심을 끌었으며, 생방 데모는 갑상선 결절, 유방 질환 및 기타 질환에 대한 응용에 초점을 맞췄습니다. 회사는 높은 참여를 보고했고 주요 기관의 외과 및 개입 리더와의 논의가 재개되었으며, congress의 모멘텀을 바탕으로 미국 및 국제 파트너십 확장을 추진할 것이라고 밝혔습니다.
Baird Medical (NASDAQ: BDMD) a conclu sa participation au ACS Clinical Congress 2025 (5-7 octobre), présentant ses systèmes d'ablation par micro-ondes (MWA) mini-invasifs à un public chirurgical mondial.
Lors de l’exposition, la technologie MWA avancée de l’entreprise a suscité un grand intérêt chez les chirurgiens de diverses spécialités, avec des démonstrations en direct axées sur les applications pour nœuds thyroïdiens, maladies du sein et d’autres conditions. L’entreprise a enregistré un fort engagement et des discussions renouvelées avec des responsables chirurgicaux et interventionnels de grandes institutions, et a indiqué qu’elle poursuivra des partenariats élargis aux États‑Unis et à l’international, en s’appuyant sur l’élan du congrès.
Baird Medical (NASDAQ: BDMD) schloss die Teilnahme am ACS Clinical Congress 2025 (5.–7. Oktober) ab und präsentierte seine minimalinvasiven Mikrowellenablation (MWA)-Systeme einem globalen chirurgischen Publikum.
Auf dem Messestand zog die fortschrittliche MWA-Technologie des Unternehmens großes Interesse von Chirurgen verschiedener Fachrichtungen auf sich, mit Live-Demos, die sich auf Anwendungen für Schilddrüsenknoten, Brusterkrankungen und andere Erkrankungen konzentrierten. Das Unternehmen meldete hohe Beteiligung und erneute Gespräche mit chirurgischen und interventionellen Führungskräften führender Institute und erklärte, dass es seine US-weiten sowie internationalen Partnerschaften ausbauen werde, gestützt durch den Kongressimpuls.
بارد ميديكال (Baird Medical, NASDAQ: BDMD) اختتمت مشاركتها في ACS Clinical Congress 2025 (5-7 أكتوبر)، مع عرض أنظمتها لعلاج بالحرارة الميكروويف (MWA) منخفضة التدخل لجمهور جراحي عالمي.
في الجناح، جذبت تكنولوجيا MWA المتقدمة في الشركة اهتمامًا كبيرًا من جراحين من تخصصات مختلفة، مع عروض حية تركز على تطبيقات لـ عُقيدات الغدة الدرقية، أمراض الثدي وغيرها من الحالات. وأشارت الشركة إلى وجود مشاركة عالية ومحادثات مجدّدة مع قادة جراحيين وتدخليين من مؤسسات رائدة، وقالت إنها ستسعى لشراكات موسعة في الولايات المتحدة وعلى المستوى الدولي مستفيدة من الزخم الناتج عن المؤتمر.
Baird Medical (NASDAQ: BDMD) 已完成在 ACS Clinical Congress 2025（2025年10月5日-7日）的参展，向全球外科观众展示其微创的 微波消融（MWA）系统。
在展位，公司的先进 MWA 技术引起了跨科室外科医生的广泛关注，现场演示聚焦于 甲状腺结节、乳腺疾病及其他病症的应用。公司报告显示参与度很高，并与来自一流机构的外科和介入领域领导者进行了新的讨论，并表示将以大会势头为基础，推动美国及国际合作伙伴关系的扩展。
- None.
- None.
At its exhibit, Baird Medical's advanced MWA systems drew significant interest from surgeons across multiple specialties. The live demonstrations were a major highlight, allowing attendees to gain hands-on experience with the technology's applications for thyroid nodules, breast disease, and other conditions. The positive reception and high level of engagement from surgeons underscored the growing demand for effective, minimally invasive treatment options.
A key success of the event was the opportunity to reconnect with prominent leaders in surgery and interventional medicine from top institutions. These collaborative discussions reinforced Baird Medical's mission to enhance patient care through technological innovation. Building on the momentum from the congress, the Company reaffirms its commitment to expanding its presence and partnerships within the
About the ACS Clinical Congress
The American College of Surgeons (ACS) Clinical Congress is one of the world's largest gatherings of surgeons, dedicated to sharing advancements in surgical techniques and improving patient care. The congress brings together thousands of professionals from across the globe to exchange knowledge and foster collaborations that advance clinical practices.
About Baird Medical
Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.
Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the
The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-concludes-successful-participation-at-acs-clinical-congress-2025-with-strong-interest-in-mwa-technology-302575471.html
SOURCE BDMD
FAQ
When did Baird Medical (BDMD) participate in ACS Clinical Congress 2025?
What BDMD technology was showcased at ACS Clinical Congress 2025?
Which clinical applications did BDMD demonstrate at the congress?
Did BDMD report surgeon interest at ACS Clinical Congress 2025?
How will BDMD use the outcomes from ACS Clinical Congress 2025?
Where can investors find more information about BDMD’s clinical outreach after the event?
